DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Purchases 30,522 Shares of Humana Inc. (NYSE:HUM)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in Humana Inc. (NYSE:HUM - Free Report) by 38.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 110,786 shares of the insurance provider's stock after buying an additional 30,522 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main owned 0.09% of Humana worth $28,108,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of HUM. Principal Financial Group Inc. boosted its position in Humana by 2.4% during the third quarter. Principal Financial Group Inc. now owns 170,636 shares of the insurance provider's stock worth $54,047,000 after purchasing an additional 3,961 shares during the period. Nordea Investment Management AB lifted its stake in Humana by 6.6% during the fourth quarter. Nordea Investment Management AB now owns 9,679 shares of the insurance provider's stock worth $2,487,000 after purchasing an additional 602 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Humana by 1.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 8,848 shares of the insurance provider's stock valued at $2,245,000 after buying an additional 138 shares in the last quarter. Ridgewood Investments LLC increased its position in Humana by 15.8% during the 4th quarter. Ridgewood Investments LLC now owns 1,026 shares of the insurance provider's stock worth $260,000 after purchasing an additional 140 shares in the last quarter. Finally, Atlas Brown Inc. boosted its holdings in shares of Humana by 0.6% during the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider's stock valued at $1,611,000 after acquiring an additional 38 shares in the last quarter. Institutional investors own 92.38% of the company's stock.

Humana Stock Performance

Shares of NYSE HUM traded up $2.94 during trading on Monday, reaching $252.47. 1,425,098 shares of the company traded hands, compared to its average volume of 1,744,233. The stock has a market capitalization of $30.47 billion, a PE ratio of 25.37, a P/E/G ratio of 2.05 and a beta of 0.49. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a 50 day simple moving average of $265.21 and a 200-day simple moving average of $270.47. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to the consensus estimate of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. The firm's revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the firm posted $7.23 earnings per share. Equities research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a dividend yield of 1.40%. Humana's payout ratio is 25.04%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on HUM shares. StockNews.com upgraded Humana from a "hold" rating to a "buy" rating in a research report on Friday. Robert W. Baird increased their price target on Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a report on Tuesday, April 15th. Oppenheimer upped their target price on shares of Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a report on Thursday, May 1st. Barclays upped their target price on shares of Humana from $270.00 to $322.00 and gave the stock an "equal weight" rating in a research note on Friday, April 11th. Finally, Guggenheim started coverage on Humana in a research note on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price objective for the company. Seventeen analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $286.81.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.